KA Imaging Makes Distribution Deal with Malaysia Based BeyMed

Summation

  • KA Imaging has entered into a distribution agreement with BeyMed for distribution of KA imaging innovative dual-energy imaging solution Reveal™ 35C in the Malaysian market.
  • BeyMed has also secured proof of concept trials that will use Reveal 35C with one of the major hospitals in Kuala Lumpur as part of the imaging solutions model in Malaysia.
  • “KA Imaging is excited to be growing rapidly and providing innovative diagnostic imaging solutions worldwide, this time signing a distribution agreement to cover Malaysia.

KA Imaging has entered into a distribution agreement with BeyMed for distribution of KA imaging innovative dual-energy imaging solution Reveal™ 35C in the Malaysian market.

“KA Imaging is excited to be growing rapidly and providing innovative diagnostic imaging solutions worldwide, this time signing a distribution agreement to cover Malaysia. BeyMed is an emerging medical solutions company with a great potential,” said Amol Karnick, President and CEO of KA Imaging.

BeyMed values offering modern, effective problem-solving through innovative technologies and strives to provide quality technology and diagnostic solutions to support radiological practices thus minimizing diagnostic errors.

Gandhi Suppiah, Managing Director of BeyMed, stated: “KA Imaging’s Reveal 35C will complement our advanced imaging technology solutions. We are excited to partner with KA Imaging to develop new imaging solutions in this part of the world.”

BeyMed has also secured proof of concept trials that will use Reveal 35C with one of the major hospitals in Kuala Lumpur as part of the imaging solutions model in Malaysia.

Reveal 35C is the world’s first and only portable dual-energy X-ray detector. The detector provides radiologists and medical professionals with three unobstructed images in a single shot with ZERO motion artifacts for better patient care. Reveal is currently being proudly used in a few clinical trials in Canada, for detecting abnormalities like lung cancer and pneumonia (including COVID-19) with great initial success.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy